Neurosurgical Review

, Volume 34, Issue 3, pp 297–304 | Cite as

Concurrent Graves’ disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment

  • Shigeo Ohba
  • Toru Nakagawa
  • Hideki Murakami


Several studies have shown the relation between Graves’ disease and stenosis/occlusion of intracranial arteries. To our knowledge, only 31 cases, including our case, of concurrent Graves’ disease and moyamoya syndrome or intracranial arterial stenosis/occlusion have been described. The patients were predominantly women, and their ages ranged from 10 to 54 years (mean, 29.3 years). Transient ischemic attacks and cerebral infarction were the common symptoms in these patients. Except one previous case and the present case, all cases showed thyrotoxicity when the cerebral ischemic event occurred. Among the 29 cases, in which the treatment regimen was known, antithyroid therapy was administered in 25 cases, and surgical treatment for cerebral vessel diseases was performed in 11 cases. Most of the patients eventually recovered from the neurological symptoms after medical and/or surgical treatment; one of the patients died, and one patient’s condition worsened. Although the mechanism underlying intracranial arterial occlusion or stenosis in patients with Graves’ disease has not been elucidated, several hypotheses have been described. Thyroid hormones may augment vascular sensitivity to the sympathetic nervous system and induce pathological changes in the arterial walls. An immune-mediated mechanism may play a role in the pathogenesis of these diseases. Atherosclerosis may be associated with these disorders. Vasculitis induced by antithyroid drugs may cause changes in the intracranial arteries. Finally, the possibility of a mere coincidence of Graves’ disease and these vascular changes should also be considered. Cerebrovascular hemodynamic changes induced by thyrotoxicosis were considered to be responsible for the cerebral ischemic events. Excessive thyroid hormone production is considered to increase the cerebral metabolism and oxygen consumption. In addition, thyrotoxicosis-induced hypercoagulability may influence ischemic events. Therefore, the possibility of thyrotoxicosis should be considered when patients with Graves’ disease show exacerbation of cerebral ischemic symptoms at follow-up. The necessity of surgery in addition to antithyroid therapy might be dependent on the mechanisms of the vascular changes and symptoms. If hyperthyroidism is associated with vascular changes and symptoms, antithyroid therapy may be adequate. However, if immune-mediated mechanisms or coincidences are considered to be associated with vascular changes and symptoms, like our case, surgical procedures might be needed.


Graves’ disease Hypothyroid Moyamoya syndrome 



  1. 1.
    Suzuki J, Takaku A (1969) Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288–299PubMedGoogle Scholar
  2. 2.
    Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease). Research committee on spontaneous occlusion of the circle of Willis (Moyamoya Disease) of the ministry of health and welfare, Japan. Clin Neurol Neurosurg 99(Suppl 2):S238–S240PubMedGoogle Scholar
  3. 3.
    Hsu SW, Chaloupka JC, Fattal D (2006) Rapidly progressive fatal bihemispheric infarction secondary to Moyamoya syndrome in association with Graves thyrotoxicosis. AJNR Am J Neuroradiol 27:643–647PubMedGoogle Scholar
  4. 4.
    Smith ER, McClain CD, Heeney M, Scott RM (2009) Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus 26:E10PubMedCrossRefGoogle Scholar
  5. 5.
    van Erven PM, Gabreëls FJ, Thijssen HO, Renier WO (1982) The Moya-Moya syndrome: a report of two children. Clin Neurol Neurosurg 84:179–189PubMedCrossRefGoogle Scholar
  6. 6.
    Kataoka H, Miyamoto S, Nagata I, Hatano T, Kano H, Hashimoto N (1999) Moyamoya disease showing atypical angiographic findings–two case reports. Neurol Med Chir (Tokyo) 39:294–298CrossRefGoogle Scholar
  7. 7.
    Nakamura K, Yanaka K, Ihara S, Nose T (2003) Multiple intracranial arterial stenoses around the circle of Willis in association with Graves’ disease: report of two cases. Neurosurgery 53:1210–1214PubMedCrossRefGoogle Scholar
  8. 8.
    Koc F, Yerdelen D, Koc Z (2008) Neurofibromatosis type 1 association with moyamoya disease. Int J Neurosci 118:1157–1163PubMedCrossRefGoogle Scholar
  9. 9.
    Mootha SL, Riley WJ, Brosnan PG (1999) Hypothalamic-pituitary dysfunction associated with Moyamoya disease in children. J Pediatr Endocrinol Metabol 12:449–453CrossRefGoogle Scholar
  10. 10.
    Cramer SC, Robertson RL, Dooling EC, Scott RM (1996) Moyamoya and Down syndrome. Clinical and radiological features. Stroke 27:2131–2135PubMedGoogle Scholar
  11. 11.
    Garcin B, Louissaint T, Hosseini H, Blanc R, Fénelon G (2008) Reversible chorea in association with Graves’ disease and moyamoya syndrome. Mov Disord 23:620–622PubMedCrossRefGoogle Scholar
  12. 12.
    Golomb MR, Biller J, Smith JL, Edwards-Brown M, Sanchez JC, Nebesio TD, Garg BP (2005) A 10-year-old girl with coexistent moyamoya disease and Graves’ disease. J Child Neurol 20:620–624PubMedCrossRefGoogle Scholar
  13. 13.
    Im SH, Oh CW, Kwon OK, Kim JE, Han DH (2005) Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg 102:1013–1017PubMedCrossRefGoogle Scholar
  14. 14.
    Kim JY, Kim BS, Kang JH (2001) Dilated cardiomyopathy in thyrotoxicosis and Moyamoya disease. Int J Cardiol 80:101–103PubMedCrossRefGoogle Scholar
  15. 15.
    Kushima K, Satoh Y, Ban Y, Taniyama M, Ito K, Sugita K (1991) Graves’ thyrotoxicosis and Moyamoya disease. Can J Neurol Sci 18:140–142PubMedGoogle Scholar
  16. 16.
    Lee R, Sung K, Park YM, Yu JJ, Koh YC, Chung S (2009) A case of Moyamoya disease in a girl with thyrotoxicosis. Yonsei Med J 50:594–598PubMedCrossRefGoogle Scholar
  17. 17.
    Leno C, Mateo I, Cid C, Berciano J, Sedano C (1998) Autoimmunity in Down’s syndrome: another possible mechanism of Moyamoya disease. Stroke 29:868–869PubMedGoogle Scholar
  18. 18.
    Liu JS, Juo SH, Chen WH, Chang YY, Chen SS (1994) A case of Graves’ diseases associated with intracranial moyamoya vessels and tubular stenosis of extracranial internal carotid arteries. J Formos Med Assoc 93:806–809PubMedGoogle Scholar
  19. 19.
    Ni J, Gao S, Cui LY, Li SW (2006) Intracranial arterial occlusive lesion in patients with Graves’ disease. Chin Med Sci J 21:140–144PubMedGoogle Scholar
  20. 20.
    Sasaki T, Nogawa S, Amano T (2006) Co-morbidity of moyamoya disease with Graves’ disease. Report of three cases and a review of the literature. Intern Med 45:649–653PubMedCrossRefGoogle Scholar
  21. 21.
    Shen AL, Ryu SJ, Lin SK (2006) Concurrent moyamoya disease and Graves’ thyrotoxicosis: case report and literature review. Acta Neurol Taiwan 15:114–119PubMedGoogle Scholar
  22. 22.
    Tendler BE, Shoukri K, Malchoff C, MacGillivray D, Duckrow R, Talmadge T, Ramsby GR (1997) Concurrence of Graves’ disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid 7:625–629PubMedCrossRefGoogle Scholar
  23. 23.
    Tsai MH, Tan TY, Kuo YL, Chang KC (2006) Multiple intracranial arterial stenoses in association with thyrotoxicosis: a case report. Acta Neurol Taiwan 15:105–108PubMedGoogle Scholar
  24. 24.
    Utku U, Asil T, Celik Y, Tucer D (2004) Reversible MR angiographic findings in a patient with autoimmune Grave’s disease. AJNR Am J Neuroradiol 25:1541–1543PubMedGoogle Scholar
  25. 25.
    Czarkowski M, Hilgertner L, Powałowski T, Radomski D (2002) The stiffness of the common carotid artery in patients with Graves’ disease. Int Angiol 21:152–157PubMedGoogle Scholar
  26. 26.
    Inaba M, Henmi Y, Kumeda Y, Ueda M, Nagata M, Emoto M, Ishikawa T, Ishimura E, Nishizawa Y (2002) Increased stiffness in common carotid artery in hyperthyroid Graves’ disease patients. Biomed Pharmacother 56:241–246PubMedCrossRefGoogle Scholar
  27. 27.
    Soliman M, Kaplan E, Yanagawa T, Hidaka Y, Fisfalen ME, DeGroot LJ (1995) T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. J Clin Endocrinol Metabol 80:905–914CrossRefGoogle Scholar
  28. 28.
    Panegyres PK, Morris JG, O’Neill PJ, Balleine R (1993) Moyamoya-like disease with inflammation. Eur Neurol 33:260–263PubMedCrossRefGoogle Scholar
  29. 29.
    Booth F, Yanofsky R, Ross IB, Lawrence P, Oen K (1999) Primary antiphospholipid syndrome with moyamoya-like vascular changes. Pediatr Neurosurg 31:45–48PubMedCrossRefGoogle Scholar
  30. 30.
    Matsuki Y, Kawakami M, Ishizuka T, Kawaguchi Y, Hidaka T, Suzuki K, Nakamura H (1997) SLE and Sjögren’s syndrome associated with unilateral moyamoya vessels in cerebral arteries. Scand J Rheumatol 26:392–394PubMedCrossRefGoogle Scholar
  31. 31.
    Colleran KM, Ratliff DM, Burge MR (2003) Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events. Endocr Pract 9:290–295PubMedGoogle Scholar
  32. 32.
    Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, Imano H, Ohira T, Okamura T, Naito Y, Shimamoto T (2004) Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 109:2766–2772PubMedCrossRefGoogle Scholar
  33. 33.
    Chastain MA, Russo GG, Boh EE, Chastain JB, Falabella A, Millikan LE (1999) Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature. J Am Acad Dermatol 41:757–764PubMedCrossRefGoogle Scholar
  34. 34.
    Morita S, Ueda Y, Eguchi K (2000) Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J 47:467–470PubMedCrossRefGoogle Scholar
  35. 35.
    Quax RA, Swaak AJ, Baggen MG (2009) Churg-Strauss syndrome following PTU treatment. Int J Rheumatol 2009:504105PubMedGoogle Scholar
  36. 36.
    Siegert CE, Smelt AH, de Bruin TW (1995) Superior sagittal sinus thrombosis and thyrotoxicosis. Possible association in two cases. Stroke 26:496–497PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of NeurosurgeryAshikaga Red Cross HospitalAshikagaJapan

Personalised recommendations